SeedBlink and Capital Cell unite to support tech startups in Europe

By Gloria Methri

SeedBlink, the investment & equity management platform dedicated to European tech startups, has partnered with Capital Cell, Spain’s investment platform specializing in Biotech and Healthtech. This collaboration aims to bridge the gap between innovative technology ventures and investors across Europe.

The partnership entails cross-launching opportunities, allowing both platforms to leverage their strengths in supporting tech startups in the Biotech and Healthtech sectors.

This initiative will facilitate easier access to funding and resources, vital for the growth and success of emerging companies in these fields, aiming for a more competitive Europe in the technology sector.

Furthermore, Capital Cell has initiated its €500,000 financing round on SeedBlink, aiming to expand its footprint in the Benelux region, France, and Italy. Through the move, the platform looking to create an expansive European network of investors, fostering cross-border investments and collaborative growth.

Andrei Dudoiu, Managing Partner at SeedBlink, said, “We recognised the need for unity in Europe’s innovation journey from the beginning, therefore we have embraced collaboration as the cornerstone of progress. We partner with Capital Cell, as well as venture capitalists, corporate investors, business angels, and individual investors, to increase equity ownership and accelerate technological competitiveness across Europe.”

Notably, Nimity, SeedBlink’s equity management solution, is on the roadmap for this collaboration. This implementation would enable Capital Cell’s portfolio companies to have better cap table management, implement employee stock options, maintain a better relationship with their stakeholders and secure investments more effectively in the long term.

Daniel Oliver, Founder and CEO of Capital Cell, added, “Joining forces with SeedBlink represents a significant milestone for us. Their expertise in tech startups complements our focus on Biotech and Healthtech, creating a powerful synergy. This collaboration will not only benefit our portfolio companies but also offer our investors a broader spectrum of vetted, high-potential investment opportunities.”

The partnership aims to create a nurturing context for ambitious startup funding, particularly in the sectors of Biotech and Healthtech. By fostering a robust, interconnected European investment community, this partnership is poised to accelerate the growth of startups and scale-ups, driving innovation and progress across the continent.